1887

Abstract

Equine sarcoids are highly recurrent bovine papillomavirus (BPV)-induced fibroblastic neoplasms that are the most common skin tumours in horses. In order to facilitate the study of potential equine sarcoid prophylactics or therapeutics, which can be a slow and costly process in equines, a murine model for BPV-1 protein-expressing equine sarcoid-like tumours was developed in mice through stable transfection of BPV-1 E5 and E6 in a murine fibroblast tumour cell line (K-BALB). Like equine sarcoids, these murine tumour cells (BPV-KB) were of fibroblast origin, were tumorigenic and expressed BPV-1 proteins. As an initial investigation of the preclinical potential of this tumour model for equine sarcoids prophylactics, mice were immunized with BPV-1 E5E6 Venezuelan equine encephalitis virus replicon particles, prior to BPV-KB challenge, which resulted in an increased tumour-free period compared with controls, indicating that the BPV-KB murine model may be a valuable preclinical alternative to equine clinical trials.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.000212
2015-09-01
2020-04-07
Loading full text...

Full text loading...

/deliver/fulltext/jgv/96/9/2764.html?itemId=/content/journal/jgv/10.1099/vir.0.000212&mimeType=html&fmt=ahah

References

  1. Aaronson S.A., Weaver C.A. 1971; Characterization of murine sarcoma virus (Kirsten) transformation of mouse and human cells. J Gen Virol 13:245–252 [CrossRef][PubMed]
    [Google Scholar]
  2. Ashrafi G.H., Tsirimonaki E., Marchetti B., O'Brien P.M., Sibbet G.J., Andrew L., Campo M.S. 2002; Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene 21:248–259 [CrossRef][PubMed]
    [Google Scholar]
  3. Bogaert L., Van Poucke M., De Baere C., Dewulf J., Peelman L., Ducatelle R., Gasthuys F., Martens A. 2007; Bovine papillomavirus load and mRNA expression, cell proliferation and p53 expression in four clinical types of equine sarcoid. J Gen Virol 88:2155–2161 [CrossRef][PubMed]
    [Google Scholar]
  4. Bogaert L., Martens A., Depoorter P., Gasthuys F. 2008a; Equine sarcoids–part 1: clinical presentation and epidemiology. Vlaams Diergen Tijds 77:2–9
    [Google Scholar]
  5. Bogaert L., Martens A., Van Poucke M., Ducatelle R., De Cock H., Dewulf J., De Baere C., Peelman L., Gasthuys F. 2008b; High prevalence of bovine papillomaviral DNA in the normal skin of equine sarcoid-affected and healthy horses. Vet Microbiol 129:58–68 [CrossRef][PubMed]
    [Google Scholar]
  6. Campo M.S. 2002; Animal models of papillomavirus pathogenesis. Virus Res 89:249–261 [CrossRef][PubMed]
    [Google Scholar]
  7. Chambers G., Ellsmore V.A., O'Brien P.M., Reid S.W., Love S., Campo M.S., Nasir L. 2003; Association of bovine papillomavirus with the equine sarcoid. J Gen Virol 84:1055–1062 [CrossRef][PubMed]
    [Google Scholar]
  8. de la Luz Garcia-Hernandez M., Gray A., Hubby B., Klinger O.J., Kast W.M. 2008; Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 68:861–869 [CrossRef][PubMed]
    [Google Scholar]
  9. Horwitz B.H., Burkhardt A.L., Schlegel R., DiMaio D. 1988; 44-amino-acid E5 transforming protein of bovine papillomavirus requires a hydrophobic core and specific carboxyl-terminal amino acids. Mol Cell Biol 8:4071–4078[PubMed] [CrossRef]
    [Google Scholar]
  10. Klein W.R., Bras G.E., Misdorp W., Steerenberg P.A., de Jong W.H., Tiesjema R.H., Kersjes A.W., Ruitenberg E.J. 1986; Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial. Cancer Immunol Immunother 21:133–140 [CrossRef][PubMed]
    [Google Scholar]
  11. Laatikainen A., Sarkkinen H., Syrjänen K., Mäntyjärvi R. 1990; Local immune reaction in syngeneic mice against tumorigenic and nontumorigenic BPV-transformed mouse cell lines. APMIS 98:909–915 [CrossRef][PubMed]
    [Google Scholar]
  12. Lunardi M., de Alcântara B.K., Otonel R.A., Rodrigues W.B., Alfieri A.F., Alfieri A.A. 2013; Bovine papillomavirus type 13 DNA in equine sarcoids. J Clin Microbiol 51:2167–2171 [CrossRef][PubMed]
    [Google Scholar]
  13. Mäntyjärvi R.A., Sarkkinen H., Karajalainen H., Parkkinen S., Ryhänen A., Syrjänen K., Jägerroos H., Nurmi T. 1988; Tumour-associated antigens in primary mouse fibroblasts induced by transformation with bovine papillomavirus type 1. Exp Pathol 35:25–33 [CrossRef][PubMed]
    [Google Scholar]
  14. Marchetti B., Ashrafi G.H., Tsirimonaki E., O'Brien P.M., Campo M.S. 2002; The bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and prevents their transport to the cell surface. Oncogene 21:7808–7816 [CrossRef][PubMed]
    [Google Scholar]
  15. Marchetti B., Gault E.A., Cortese M.S., Yuan Z., Ellis S.A., Nasir L., Campo M.S. 2009; Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain. J Gen Virol 90:2865–2870 [CrossRef][PubMed]
    [Google Scholar]
  16. McConaghy F.F., Davis R.E., Hodgson D.R. 1994; Equine sarcoid: a persistent therapeutic challenge. Compend Contin Educ Pract Vet 16:1022–1029
    [Google Scholar]
  17. Mohammed H.O., Rebhun W.C., Antczak D.F. 1992; Factors associated with the risk of developing sarcoid tumours in horses. Equine Vet J 24:165–168 [CrossRef][PubMed]
    [Google Scholar]
  18. Nasir L., Campo M.S. 2008; Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. Vet Dermatol 19:243–254 [CrossRef][PubMed]
    [Google Scholar]
  19. Nogueira S.A., Torres S.M., Malone E.D., Diaz S.F., Jessen C., Gilbert S. 2006; Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study. Vet Dermatol 17:259–265 [CrossRef][PubMed]
    [Google Scholar]
  20. Otten N., von Tscharner C., Lazary S., Antczak D.F., Gerber H. 1993; DNA of bovine papillomavirus type 1 and 2 in equine sarcoids: PCR detection and direct sequencing. Arch Virol 132:121–131 [CrossRef][PubMed]
    [Google Scholar]
  21. Thomas M., Pim D., Banks L. 2006; The role of the HPV E6 oncoprotein in malignant progression. In Papillomavirus Research: From Natural History to Vaccines and Beyond pp. 115–131 Edited by Saveria Campo M. Wymondham: Caister Academic Press;
    [Google Scholar]
  22. Velders M.P., McElhiney S., Cassetti M.C., Eiben G.L., Higgins T., Kovacs G.R., Elmishad A.G., Kast W.M., Smith L.R. 2001; Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 61:7861–7867[PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.000212
Loading
/content/journal/jgv/10.1099/vir.0.000212
Loading

Data & Media loading...

Supplements

Supplementary Data

PDF

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error